Prakt. lékáren. 2022; 18(3): 160-162 | DOI: 10.36290/lek.2022.033

Personalised medicine in oncology - the role of the pharmacist

Vojtěch Ondra
Ústavní lékárna, Masarykův onkologický ústav, Brno
Farmakologický ústav, Lékařská fakulta, Masarykova univerzita Brno

Molecular biology and genetics bring new understandings to the dynamics of the biology of tumors which allows better diagnostics and new targets for treatment. This article describes how is this knowledge used for the personalization of oncology treatment and the possible involvement of pharmacists.

Keywords: personalised medicine, targeted therapy, unregistered drugs.

Accepted: October 13, 2022; Published: October 27, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ondra V. Personalised medicine in oncology - the role of the pharmacist. Praktické lékárenství. 2022;18(3):160-162. doi: 10.36290/lek.2022.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kumar­‑Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol. 2018;36(1):46-60. doi:10.1038/nbt.4017. Go to original source... Go to PubMed...
    2. Smith CEP, Prasad V. Targeted Cancer Therapies. AMERICAN FAMILY PHYSICIAN. 2021;103(3):155-163. Dostupné z: https://pubmed.ncbi.nlm.nih.gov/33507053/. Go to PubMed...
    3. Státní ústav pro kontrolu léčiv, 2022. Souhrn údajů o přípravku Enhertu [online] Cit. 2022-07-20. Dostupné z: https://www.ema.europa.eu/en/documents/product­‑information/enhertu­‑epar­‑product­‑information_cs.pdf.
    4. Looney AM, Nawaz K, Webster RM. Tumour­‑agnostic therapies. Nature Reviews Drug Discovery. 2020;19(6):383-384. doi:10.1038/d41573-020-00015-1. Go to original source... Go to PubMed...
    5. 2018 ASCO: IMPACT Trial Matches Treatment to Genetic Changes in the Tumor to Improve Survival Across Multiple Cancer Types - The ASCO Post. Accessed May 25, 2021. https://ascopost.com/news/58897.
    6. Schwaederle M, Zhao M, Lee JJ, et al. Impact of Precision Medicine in Diverse Cancers: A Meta­‑Analysis of Phase II Clinical Trials. J Clin Oncol. 2015;33(32):3817-3825. doi:10.1200/JCO.2015. 61. 5997. Go to original source...
    7. Tsimberidou AM, Hong DS, Wheler JJ, et al. Precision medicine: Clinical outcomes including long­‑term survival according to the pathway targeted and treatment period-The IMPACT study. JCO. 2018;36(18_suppl):LBA2553-LBA2553. doi:10.1200/JCO.2018. 36. 18_suppl.LBA2553. Go to original source... Go to PubMed...
    8. Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfiLER study. | Journal of Clinical Oncology. Accessed May 25, 2021. https://ascopubs.org/doi/abs/10.1200/JCO.2017. 35. 18_suppl.LBA100.
    9. Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The Role of Next­‑Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. Journal of Personalized Medicine. 2018;8(3). doi:10.3390/jpm8030030. Go to original source... Go to PubMed...
    10. Slabý O, Dundr P, Grell P, et al. I. Blok: Precizní farmakoterapie v solidní onkologii. VIII. konference PharmAround, Brno, 27. 4. 2022.
    11. Dundr P. Komplexní prediktivní testování u solidních nádorů metodou NGS >> Linkos.cz. Linkos. Published May 26, 2021. Accessed July 20, 2022. https://www.linkos.cz/lekar­‑a-multidisciplinarni­‑tym/personalizovana­‑onkologie/precizni­‑onkologie/komplexni­‑prediktivni­‑testovani­‑u-solidnich­‑nadoru­‑metodou­‑ngs/.
    12. Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology. 2018;29(9):1895-1902. doi:10.1093/annonc/mdy263. Go to original source... Go to PubMed...
    13. info@aion.cz AC. 48/1997 Sb. Zákon o veřejném zdravotním pojištění. Zákony pro lidi. Accessed July 20, 2022. https://www.zakonyprolidi.cz/cs/1997-48.
    14. Davidová J, Buchtová I, Čechová R, Tomanová L. Doporučený postup - Neregistrované léčivé přípravky. Published online May 30, 2019. Dostupné z: https://lekarnici.cz/Vzdelavani/Doporucene­‑postupy/Doporuceny­‑postup­‑Neregistrovane­‑lecive­‑pripravk.aspx.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.